The National Institutes of Health (NIH) has announced a $33.2 million grant to the Banner Alzheimer’s Institute to carry out the first U.S.-based Alzheimer’s prevention trials, according to an NIH release. Scientists will look for ways to stave off the disease in mentally healthy older adults at the highest known genetic risk for developing the disease. Researchers will test an anti-amyloid treatment in 60- to 75-year-olds who have two copies of the apolipoprotein E (APOE4) gene, which is the major genetic risk factor for late-onset Alzheimer’s. The trial will draw participants from the Alzheimer’s Prevention Registry and is part of the Alzheimer’s Prevention Initiative (API), an international collaboration to accelerate prevention therapies.

To read the press release, click here.